SYNOPSIS
of the MLL and AF4 gene structures, [5] [6] [7] with specific emphasis on the breakpoint cluster regions (bcrs) of both genes. The bcr of MLL was already published some years ago (Genbank accession codes: U04737 and X83604), 8, 9 and more recently the 52 kb long bcr of the AF4 gene was completely sequenced (Genbank accession code: AJ238093). 10 The AF4 sequence was used to create specific sets of oligonucleotides that cover all parts of the AF4 bcr. These oligonucleotides were combined with two oligonucleotides specifically binding to the flanking areas of the MLL bcr ( Figure 1 , primers A and B). In 16 individual PCR reactions using the combination of only one MLL-and 16 AF4-specific oligonucleotides, the genomic fusion site of a given derivative chromosome can be identified ( Figure 1 ; for details see Ref. 10) . Usually, the first 16 PCR reactions identify a given derivative 11 breakpoint and define approximately the location of the reciprocal breakpoint on the derivative 4 chromosome. Thus, only three or four PCR reactions have to be used for the identification of the reciprocal breakpoint on the derivative 4 chromosome. Using this approach, genomic breakpoints of one or two rearranged derivative chromosomes can be identified quickly by using only 2 g of isolated patient genomic DNA.
Subsequent mapping, cloning and sequencing of the chromosomal fusion sites resulted in patient-specific DNA tumor markers. For this purpose, four novel oligonucleotides have to be designed for each patient and his derivative chromosomes. This step is necessary because all oligonucleotides that were used in the initial DNA diagnosis are very long primers (Ͼ30 mers) and the amplified products are usually between 5 and 25 kb. Long-range PCR is optimized for long PCR products, however, the detection limit is only about one tumor cell in 1000 normal cells after 35 PCR cycles (sensitivity: 10 −3 ). In contrast, the four patient-specific oligonucleotides are designed to amplify DNA fragments in the range of 500 bp to 3 kb. The sensitivity of this experiment using normal PCR conditions was about one tumor cell in 10 5 or 10 6 normal cells (sensitivity: 10 −5 to 10 −6 ). This method, applied only for t(4;11) translocations, gave positive results even in situations when no fusion mRNA can be detected in the leukemic blasts (eg during therapy) and RT-PCR techniques would have failed to give a positive result.
Using this technique, the fine structure of chromosomal fusion sites of t(4;11) cell lines and a significant set of t(4;11) patients were analyzed. 11 The results provided valuable information for scientific and clinical questions. First, chromosomal breakpoints were not balanced. In none of the t(4;11) cell lines nor patients were the chromosomal breakpoints generated by simple cross-over mechanisms. In contrast, parental DNA fragments (5 to 2.750 bp long DNA fragments; medium size was several hundred bp) were either duplicated (43%), deleted (51%) or inverted (6%). In 51% of all cases, minidirect repeats were identified at the chromosomal fusion sites. This indicated a severe DNA damage situation prior to a subsequent DNA repair process according to the rules of the 'non-homologous DNA end joining (NHEJ)' pathway, as summarized recently. 11, 12 According to this scenario, t(4;11) trans-
Figure 1
Breakpoint analysis on derivative chromosomes in t(4;11) ALL. Upper part, scheme of the breakpoint cluster regions (bcr) of the human MLL and AF4 genes (sizes are indicated). Large boxes, exons; small boxes, introns; bold numbers, exon numbers; A, B, MLL-specific oligonucleotides; 1-32, AF4-specific oligonucleotides; lower part, examples for derivative 11 analysis (primer combinations are indicated); left, analysis for a t(4;11)-positive patient; right, analysis of a t(4;11)-negative patient; negative, negative control using no genomic DNA; positive, positive control using the primer combination A and B; standard, PStI-digested lambda DNA.
locations are the result of 'DNA damage' and impaired or misguided 'DNA repair'. Second, first subclusters were identified in the AF4 bcr (clusters I to III). Interestingly, leukemic patients below 1 year of age had their breakpoints mostly in the telomeric portion of the MLL bcr (seven out of nine: 77%), while AF4 breakpoints were located in the centromeric portion of the AF4 bcr (cluster I; five out of nine: 55%). For all other de novo t(4;11) patients analyzed so far, no preferences for breakpoints in the AF4 clusters I to III were observed, however, most breaks (26 out of 38: 68%) were clustered in the centromeric portion of the MLL bcr. Third, the information about chromosomal breakpoints is patient-specific and was used for MRD-monitoring of residual tumor cells in isolated DNA of t(4;11) leukemia patients (M Lode, unpublished data). Using patient-specific sets of oligonucleotides, PCR amplification of chromosomal breakpoints was highly sensitive, reproducible and virtually gave no background. Finally, this method was not only applicable for quantifying residual leukemic blasts in t(4;11) patients, but also to identify pre-leukemic cells on Guthrie test cards. 13, 14 
